Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GTx and Tessera form prostate cancer test deal:

This article was originally published in Clinica

Executive Summary

In what could lead to a marriage of therapy and diagnostics for prostate cancer, biopharmaceutical firm GTx has linked up with Tessera to develop a blood or urine test for premalignant prostate lesions that can become cancerous. Under the agreement, Memphis, Tennessee-based GTx will provide clinical samples from its completed phase IIb clinical trial of its Acapodene (toremifene citrate) agent for reducing the incidence of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN). Tessera's early prostate cancer antigen, ProstaMark, will be used to identify patients with PIN lesions and/or early-stage prostate cancer.

You may also be interested in...



FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

Stada Grabs GSK Brands In EU

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.

Topics

UsernamePublicRestriction

Register

MT059336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel